Donald Trump’s Tariffs: Coming To Your Medicine Cabinet Soon

Key Concepts:

• Tariffs on pharmaceuticals
• Generic drug manufacturers
• Brand-name medications
• Imported components for drug manufacturing
• Impact on consumer drug costs
• Trade war and its consequences on the pharmaceutical industry

1. Trump's Tariffs and the Pharmaceutical Industry

• President Trump's tariffs, enacted as a core campaign promise, are impacting the pharmaceutical industry.
• Initially, a baseline 10% tariff was imposed on imports from all countries, with China, India, and EU countries facing potentially higher rates.
• Trump announced a pause on most reciprocal tariffs except China, which was hit with a 125% levy, up from 104% a day earlier.
• Pharmaceuticals are currently exempt from China's retaliatory tariffs, but this is expected to change.
• Trump suggested pharmaceutical companies would face a "big tax" if they didn't "come roaring back," indicating potential future tariffs.

2. Impact on Generic Drug Manufacturers

• Generic drug manufacturers, accounting for about 90% of all prescriptions in the US, are particularly vulnerable.
• About 47% of all generics prescribed in the US are made in India, which was facing a 26% tariff before the pause.
• Many generic drugs, like some heart medications costing less than a dollar a pill, have low profit margins.
• Rajie Levventhal (Earketer) stated that tariffs could force manufacturers to reconsider their market presence, potentially hurting consumers who rely on low-cost alternatives.

3. Examples of Cost Increases

• Mark Cuban (Cost Plus Drug Company) stated that any costs elevated by tariffs will be passed through to patients.
• ING analyst Dedric Stadig estimated that a 24-week course of generic cancer medication could cost as high as $10,000 under a 25% tariff.

4. Impact on Brand-Name Medications

• Brand-name medications manufactured in EU countries, which were facing a 20% tariff, are also affected.
• Examples include weight loss medication Wegovy, cancer immunotherapy drug Keytruda, and HIV drug Norvir.
• For a patient whose insurance doesn't cover Wegovy, this could mean an extra $100 a month if Novo Nordisk passed on the whole tariff cost.

5. Impact on Canadian Pharmaceuticals

• A JAMA analysis suggested that tariffs on Canadian pharmaceuticals alone would increase annual drug costs in the US by $750 million a year.

6. Reliance on Imported Components

• Nearly 90% of American biotech companies rely on imported components for a significant portion of their FDA products.
• Cancer drug Opdivo, for example, imports a key ingredient from China, which produces about 72% of the pharmaceutical ingredients imported to the US.
• Finding alternative suppliers could take more than 2 years for nearly half of the responding biotechs.

7. Impact on Manufacturing Capacity

• There is insufficient domestic manufacturing capacity to meet demand, making reliance on imports necessary.

8. Potential Long-Term Consequences

• Or Inbar (Quant Health) noted that a trade war could lead larger pharma companies to build multiple manufacturing facilities globally to avoid tariffs.
• While this might mitigate the impact, it would still raise costs due to increased overhead and management expenses, which would ultimately be passed on to consumers.
• "The more sites you have the more overhead and management costs you have and those costs would ultimately be passed on to consumers." - Or Inbar (Quant Health)

9. Conclusion

• Trump's tariffs are poised to significantly impact the pharmaceutical industry, potentially leading to increased drug costs for American consumers.
• Both generic and brand-name medications are affected, as well as the reliance on imported components for drug manufacturing.
• The trade war could lead to long-term changes in manufacturing strategies, ultimately resulting in higher costs for patients.